Syros Pharmaceuticals (NASDAQ:SYRS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.

A number of other equities analysts have also recently commented on SYRS. HC Wainwright reissued a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Syros Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

Shares of Syros Pharmaceuticals stock opened at $0.08 on Wednesday. The business has a 50 day simple moving average of $0.19 and a two-hundred day simple moving average of $0.96. Syros Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $7.27. The stock has a market capitalization of $2.20 million, a P/E ratio of -0.03 and a beta of 1.29.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SYRS. Two Sigma Securities LLC acquired a new stake in shares of Syros Pharmaceuticals in the fourth quarter valued at approximately $25,000. GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals in the third quarter worth approximately $34,000. Finally, Exome Asset Management LLC grew its position in Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after acquiring an additional 139,400 shares during the period. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.